These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment. Lv Y; Li M; Weng L; Huang H; Mao Y; Yang DA; Wei Q; Zhao M; Wei Q; Rui K; Han X; Fan W; Cai X; Cao P; Cao M J Exp Clin Cancer Res; 2023 Nov; 42(1):322. PubMed ID: 38012650 [TBL] [Abstract][Full Text] [Related]
14. Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway. Qi X; Jiang H; Liu P; Xie N; Fu R; Wang H; Liu C; Zhang T; Wang H; Shao Z Leuk Lymphoma; 2021 Jan; 62(1):218-223. PubMed ID: 32985300 [TBL] [Abstract][Full Text] [Related]
15. Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues. Jang TJ; Kim SA; Kim MK Pathol Res Pract; 2018 Aug; 214(8):1179-1184. PubMed ID: 29970307 [TBL] [Abstract][Full Text] [Related]
16. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. Weis-Banke SE; Hübbe ML; Holmström MO; Jørgensen MA; Bendtsen SK; Martinenaite E; Carretta M; Svane IM; Ødum N; Pedersen AW; Met Ö; Madsen DH; Andersen MH Oncoimmunology; 2020 Jun; 9(1):1771142. PubMed ID: 32923127 [TBL] [Abstract][Full Text] [Related]
17. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148 [TBL] [Abstract][Full Text] [Related]
18. A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment. Pilanc P; Wojnicki K; Roura AJ; Cyranowski S; Ellert-Miklaszewska A; Ochocka N; Gielniewski B; Grzybowski MM; Błaszczyk R; Stańczak PS; Dobrzański P; Kaminska B Front Oncol; 2021; 11():703465. PubMed ID: 34504786 [TBL] [Abstract][Full Text] [Related]
19. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Martinenaite E; Ahmad SM; Bendtsen SK; Jørgensen MA; Weis-Banke SE; Svane IM; Andersen MH Cancer Immunol Immunother; 2019 Nov; 68(11):1901-1907. PubMed ID: 31690955 [TBL] [Abstract][Full Text] [Related]
20. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial. Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM Front Immunol; 2022; 13():1023023. PubMed ID: 36330525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]